Antares' Oxybutynin Gel Product Approved by FDA for the Treatment of Overactive Bladder

Watson Pharmaceuticals, Inc. WPI and Antares Pharma, Inc. AIS today announced that the U.S. Food and Drug Administration has approved Antares' topical oxybutynin gel 3% product for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. OAB is a condition that affects more than 33 million Americans, and the market currently exceeds $2.0 billion annually.